2. Apoptosis
  3. Apoptosis
  4. XPO1-IN-1

XPO1-IN-1 (compound D4) is an orally active and potent XPO1 inhibitor, with an IC50 of 24 nM in MM.1S cell. XPO1-IN-1 can efficiently induce cell apoptosis and cell cycle arrest. XPO1-IN-1 displays favorable metabolic stability and pharmacokinetic properties. XPO1-IN-1 can be used for multiple myeloma (MM) research.

For research use only. We do not sell to patients.

XPO1-IN-1 Chemical Structure

XPO1-IN-1 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

XPO1-IN-1 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

XPO1-IN-1 (compound D4) is an orally active and potent XPO1 inhibitor, with an IC50 of 24 nM in MM.1S cell. XPO1-IN-1 can efficiently induce cell apoptosis and cell cycle arrest. XPO1-IN-1 displays favorable metabolic stability and pharmacokinetic properties. XPO1-IN-1 can be used for multiple myeloma (MM) research[1].

IC50 & Target

XPO1

 

In Vitro

XPO1-IN-1 (compound D4) (24 h) shows high anti-proliferation efficacy in MM.1S cell and lymphomatous cell lines[1].
XPO1-IN-1 (0-10 μM, 24 h) induces cancer cell cycle arrest[1].
XPO1-IN-1 (0-10 μM, 48 h) induces apoptosis of MM.1S cell[1].
XPO1-IN-1 (0-10 μM, 2 h) inhibits XPO1-dependent nuclear export[1].
XPO1-IN-1 shows the good metabolic stability, with more than 80% intact compound remained over rat plasma (2 h), and around 85% intact compound remained in liver microsomes (1 h)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

XPO1-IN-1 Related Antibodies

Cell Proliferation Assay

Cell Line: MM.1S, Mino, VAL, Rael, Namaiwa, Mutu, H9, JB6, and YT[1]
Concentration:
Incubation Time: 24 h
Result: Showed high anti-proliferation efficacy in MM.1S cell and lymphomatous cell lines (Mino, VAL, Rael, Namaiwa, Mutu, H9, JB6, and YT), with IC50 values of 24, 80.2, 189.1, 201.8, 77.7, 158.2, 101.1, 154.1, and 75.4 nM, respectively.

Cell Cycle Analysis

Cell Line: MM.1S cell[1]
Concentration: 0, 0.1, 1, 5, and 10 μM
Incubation Time: 24 h
Result: Induced cancer cell cycle arrest in high concentration (>100 nM), increased the population of cells arrested in G2 to 37.3% in 5 μM.

Apoptosis Analysis

Cell Line: MM.1S cell[1]
Concentration: 0, 0.1, 1, and 10 μM
Incubation Time: 48 h
Result: Induced apoptosis, significantly increased the apoptotic cell rate to 64.7% (10 μM) when compared to the sample with negative control (6.7%).

Immunofluorescence

Cell Line: MM.1S cell[1]
Concentration: 0, 0.1, 1, and 10 μM
Incubation Time: 2 h
Result: Inhibited XPO1-dependent nuclear export.
In Vivo

XPO1-IN-1 (compound D4) (Sprague Dawley rats; 10 mg/kg, IG; 1 mg/kg, IV; once) shows a good pharmacokinetic properties[1]. Pharmacokinetic Parameters of XPO1-IN-1 in SD rats[1].

Parameters i.g. (10 mg/kg) i.v. (1 mg/kg)
Tmax (h) 2.17 ± 1.76 0.08
T1/2 (h) 2.12 ± 0.16 2.32 ± 0.17
Cmax (ng/mL) 1391.27 ± 586.77 1239.08 ± 152.54
AUC0-t (ng/mL·h) 5774.13 ± 1461.41 1668.03 ± 229.48
AUC0-∞ (ng/mL·h) 6387.17 ± 1637.18 1791.40 ± 236.56
CL (mL/h/kg) 1638.65 ± 431.97 565.30 ± 80.40
F (%) 34.6

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague Dawley rats[1]
Dosage: 10 mg/kg (IG), 1 mg/kg (IV)
Administration: Oral gavage (IG), IV, once (Pharmacokinetic Analysis)
Result: Showed a good pharmacokinetic properties, with relatively long half-life of 2.12 h (IG) and 2.32 h (IV), respectively, and decent bioavailability F (%) of 34.6%.
Molecular Weight

519.42

Formula

C20H15F6N5O3S
SMILES

CS(=O)(NC1=CC=C(C=C1)/C(C(N)=O)=C\N2C=NC(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)=N2)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

XPO1-IN-1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

XPO1-IN-1ApoptosisMultiple myeloma (MM)MM.1S cellLymphomaOrally activeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
XPO1-IN-1
Cat. No.:
HY-144763
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.